Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
- PMID: 31462645
- PMCID: PMC6713756
- DOI: 10.1038/s41467-019-11812-7
Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
Abstract
Genetic studies have advanced our understanding of pancreatic cancer at a mechanistic and translational level. Genetic concepts and tools are increasingly starting to be applied to clinical practice, in particular for precision medicine efforts. However, epigenomics is rapidly emerging as a promising conceptual and methodological paradigm for advancing the knowledge of this disease. More importantly, recent studies have uncovered potentially actionable pathways, which support the prediction that future trials for pancreatic cancer will involve the vigorous testing of epigenomic therapeutics. Thus, epigenomics promises to generate a significant amount of new knowledge of both biological and medical importance.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
-
- Aguirre AJ, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 2018;8:1096. doi: 10.1158/2159-8290.CD-18-0275. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
